Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?
- PMID: 28786414
- DOI: 10.1038/nrclinonc.2017.125
Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?
Comment on
-
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous